Skip to content
Screener

LivaNova LIVN Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Haemonetics logo
HaemoneticsHAE
$0.010.0%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$0.000.0%
ITG
Integer HoldingsITGR
$0.000.0%
CONMED logo
CONMEDCNMD
$0.010.0%
Artivion logo
ArtivionAORT
$0.010.0%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemJune 30, 2026December 31, 2025
Total Liabilities1,315,5391,406,066
Commitments and contingencies (Note 6)
Shareholders’ Equity:
Ordinary Shares, £1.00 par value: Unlimited shares authorized; 55,601,145 shares issued and 55,051,768 shares outstanding as of June 30, 2026; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 202584,59984,564
Additional paid-in capital2,270,6992,254,980
Accumulated other comprehensive (loss) income(14,386)7,330
Accumulated deficit(1,014,858)(1,145,721)
Treasury shares at cost, 549,377 ordinary shares as of June 30, 2026; 886,096 ordinary shares as of December 31, 2025(732)(1,166)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's common stock par value per share?
LivaNova (LIVN) reported common stock par value per share of $1.00 in Q2 2026.
How has LivaNova's common stock par value per share changed year-over-year?
LivaNova's common stock par value per share decreased by 0.0% year-over-year, from $1.00 to $1.00.
What is the long-term trend for LivaNova's common stock par value per share?
Over 5 years (2020 to 2025), LivaNova's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $1.00 to $1.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about LivaNova's common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude